Skip to main content
Top

28-04-2024 | Cholangiocarcinoma | Hepatobiliary Tumors

Is Repeat Resection for Recurrent Intrahepatic Cholangiocarcinoma Warranted?

Author: Lavanya Yohanathan, MD

Published in: Annals of Surgical Oncology

Login to get access

Excerpt

Intrahepatic cholangiocarcinoma (ICCA) is the second most common liver cancer (following hepatocellular cancer), accounting for 5–10% of all liver cancers.1 The incidence continues to rise in the US and worldwide and can be attributed to increased utility of cross-sectional imaging.24 Surgical resection remains the only curative intent modality for this disease. Only 10–40% of patients are considered candidates for surgical resection, and 5 year survival rates are poor (25–40%) despite R0 resection.58 This corroborates that despite optimal treatment and surgical resection with negative margins, ICCA continues to have an aggressive clinical course, natural history, and tumor biology.912
Literature
1.
go back to reference Kudo M, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, et al. Report of the 20th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2020;50(1):15–46.CrossRefPubMedPubMedCentral Kudo M, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, et al. Report of the 20th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2020;50(1):15–46.CrossRefPubMedPubMedCentral
4.
go back to reference Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84–96.CrossRefPubMed Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84–96.CrossRefPubMed
5.
go back to reference Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–89.CrossRefPubMed Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–89.CrossRefPubMed
7.
go back to reference Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg. 2001;193(4):384–91.CrossRefPubMed Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg. 2001;193(4):384–91.CrossRefPubMed
9.
go back to reference Nuzzo G, Giuliante F, Ardito F, et al. Intrahepatic cholangio-carcinoma: prognostic factors after liver resection. Updates Surg. 2010;62(1):11–9.CrossRefPubMed Nuzzo G, Giuliante F, Ardito F, et al. Intrahepatic cholangio-carcinoma: prognostic factors after liver resection. Updates Surg. 2010;62(1):11–9.CrossRefPubMed
10.
go back to reference Chen LP, Li C, Wang C, Wen TF, Yan LN, Li B. Predictive factors of recurrence for patients with intrahepatic cholangiocarcinoma after hepatectomy. Hepato-gastroenterol. 2012;59(118):1765–8. Chen LP, Li C, Wang C, Wen TF, Yan LN, Li B. Predictive factors of recurrence for patients with intrahepatic cholangiocarcinoma after hepatectomy. Hepato-gastroenterol. 2012;59(118):1765–8.
11.
go back to reference Hanazaki K, Kajikawa S, Shimozawa N, et al. Prognostic factors ofintrahepatic cholangiocarcinoma after hepatic resection: univariateand multivariate analysis. Hepato-gastroenterol. 2002;49(44):311–6. Hanazaki K, Kajikawa S, Shimozawa N, et al. Prognostic factors ofintrahepatic cholangiocarcinoma after hepatic resection: univariateand multivariate analysis. Hepato-gastroenterol. 2002;49(44):311–6.
12.
go back to reference Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarci-noma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84–96.CrossRefPubMed Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarci-noma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84–96.CrossRefPubMed
14.
go back to reference Zhang XF, Beal EW, Bagante F, Chakedis J, Weiss M, Popescu I, et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg. 2018;105(7):848–56.CrossRefPubMed Zhang XF, Beal EW, Bagante F, Chakedis J, Weiss M, Popescu I, et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg. 2018;105(7):848–56.CrossRefPubMed
15.
go back to reference Hyder O, Marques H, Pulitano C, Marsh JW, Alexandrescu S, Bauer TW, et al. A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an eastern and western experience. JAMA Surg. 2014;149(5):432–8.CrossRefPubMed Hyder O, Marques H, Pulitano C, Marsh JW, Alexandrescu S, Bauer TW, et al. A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an eastern and western experience. JAMA Surg. 2014;149(5):432–8.CrossRefPubMed
16.
go back to reference Sahara K, Tsilimigras DI, Mehta R, Bagante F, Guglielmi A, Aldrighetti L, et al. A novel online prognostic tool to predict long-term survival after liver resection for intrahepatic cholangiocarcinoma: the “metro-ticket”paradigm. J Surg Oncol. 2019;120(2):223–30.CrossRefPubMed Sahara K, Tsilimigras DI, Mehta R, Bagante F, Guglielmi A, Aldrighetti L, et al. A novel online prognostic tool to predict long-term survival after liver resection for intrahepatic cholangiocarcinoma: the “metro-ticket”paradigm. J Surg Oncol. 2019;120(2):223–30.CrossRefPubMed
17.
go back to reference Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, et al. Prognostic nomogram forintrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31(9):1188–95.CrossRefPubMed Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, et al. Prognostic nomogram forintrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31(9):1188–95.CrossRefPubMed
18.
go back to reference Lu WF, Chen PQ, Yan K, Wu YC, Liang L, Yuan JY, et al. Synergistic impact of resection margin and microscopic vascular invasion for patients with HBV-related intrahepatic cholangiocarcinoma. Expert Rev Gastroenterol Hepatol. 2021;15(5):575–82.CrossRefPubMed Lu WF, Chen PQ, Yan K, Wu YC, Liang L, Yuan JY, et al. Synergistic impact of resection margin and microscopic vascular invasion for patients with HBV-related intrahepatic cholangiocarcinoma. Expert Rev Gastroenterol Hepatol. 2021;15(5):575–82.CrossRefPubMed
20.
go back to reference Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663–73.CrossRefPubMed Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663–73.CrossRefPubMed
Metadata
Title
Is Repeat Resection for Recurrent Intrahepatic Cholangiocarcinoma Warranted?
Author
Lavanya Yohanathan, MD
Publication date
28-04-2024
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-024-15253-5